Business
H-CYTE Bolsters Board of Directors With Appointment of Dr. Atta Behfar to its Board of Directors
H-CYTE Bolsters Board of Directors With Appointment of Dr. Atta Behfar to its Board of Directors.
About this update from Innoveren Scientific Inc.
[{"type":"text","content":"\nTAMPA, Fla., July 30, 2019 (GLOBE NEWSWIRE) -- H-CYTE Inc. (OTCQB: HCYT) (“H-CYTE” or the “Company”), the owner and operator of innovative medical technology products and services including Lung Health Institute, today announced it has appointed Dr. Atta Behfar to its Board of Directors.\n\n \n \n \n \n \n \n \n \n \n \n \n Atta Behfar, M.D., Ph.D.\n \n \n \n \n \n \n \n \n\n Atta Behfar, M.D., Ph.D., is a transplant cardiologist and Associate Professor of Medicine at Mayo Clinic. He leads translational and CGMP manufacturing activities in the Center for Regenerative Medicine and is Director of the Van Cleve Cardiac Regenerative Medicine Program at Mayo Clinic. He is a Co-Founder of Rion with the goal of developing off-the-shelf exosome-based regenerative biotechnologies for soft tissue, cardiovascular and solid-organ disease. His expertise in the areas of regenerative medicine and continued focus on emerging treatments allows him to bring a future-minded lens to the H-CYTE board. Dr. Behfar, along with leading clinical and translational efforts in regenerative medicine, focuses his research on heart disease prevention and treatment. His team oversees pre-clinical and clinical efforts to better identify, treat and cure cardiovascular disease. He received his medical degree at the Mayo Clinic College of Medicine and a doctorate in Molecular Pharmacology and Experimental Therapeutics at the Mayo Graduate School. He earned a Bachelor of Science in Biochemistry from Marquette University, Magna Cum Laude. \"I’m extremely pleased to have Dr. Behfar on our board of directors. His involvement lends additional expertise to our world-class team of experts in biotech and health care. With our recently executed agreement with Rion, we believe the addition of Drs. Behfar and Terzic to our team is a key step toward continued research and anticipated commercialization of our promising new cellular treatment for chronic lung conditions like chronic obstructive pulmonary disease (COPD). COPD is the fourth leading cause of death in the U.S., and successful realization of this treatment would be the first breakthrough therapy in years for people with chronic lung disease,” said William Horne, H-CYTE CEO and Chairman. “Because H-CYTE and Rion are so aligned on finding effective treatments for people with ...